The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy
Abstract
Leukocyte Fcγ receptors (FcγR) confer potent cellular effector functions to the specificity of IgG. FcγR‐induced leukocyte functions, including antibody‐dependent cellular cytotoxicity, phagocytosis, superoxide generation, degranulation, cytokine production and regulation of antibody production, are essential for host defense and immune regulation. The efficacy of IgG‐induced FcγR function displays inter‐individual heterogeneity due to genetic polymorphisms of three FcγR subclasses, FcγRIIa (CD32a), FcγRIIIa (CD16a), and FcγRIIIb (CD16b). FcγR polymorphisms have been associated with infectious and autoimmune disease, or with disease severity. FcγR polymorphisms may furthermore serve as markers for therapeutic efficacy and side‐effects of treatment with monoclonal antibodies. In this review, FcγR function and the relevance of FcγR polymorphisms as prognostic markers for inflammatory disease and antibody‐based immunotherapy are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Koene, H. R., Kleijer, M., Algra, J., Roos, D., E.G.Kr. von dem Borne, A., & de Haas, M. (1997) · Blood · doi:10.1182/blood.v90.3.1109 · Cited by 794
An Fc receptor structurally related to MHC class I antigens
Simister, N. E., & Mostov, K. E. (1989) · Nature · doi:10.1038/337184a0 · Cited by 729
Wu, J., Edberg, J. C., Redecha, P. B., Bansal, V, Guyre, P. M., Coleman, K., Salmon, J. E., & Kimberly, R. P. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119616 · Cited by 711
Junghans, R. P., & Anderson, C. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.11.5512 · Cited by 684
Deletion of SHIP or SHP-1 Reveals Two Distinct Pathways for Inhibitory Signaling
Ono, M., Okada, H., Bolland, S., Yanagi, S., Kurosaki, T., & Ravetch, J. V. (1997) · Cell · doi:10.1016/s0092-8674(00)80337-2 · Cited by 499
Multiple Roles for the Major Histocompatibility Complex Class I– Related Receptor FcRn
Ghetie, V., & Ward, E. S. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.739 · Cited by 474
Warmerdam, P. A., van de Winkel, J. G., Vlug, A., Westerdaal, N. A., & Capel, P. J. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.4.1338 · Cited by 463
Self-citation
Cited by
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions
Boruchov, A. M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24772 · Cited by 377
Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353
Metadata
- Authors
- Van Sorge, N. M., Van Der Pol, W., & Van De Winkel, J. G. J.
- Venue
- Tissue Antigens
- Publisher
- Wiley
- Published
- 2003-03
- Volume
- 61
- Issue
- 3
- Pages
- 189-202
- ISSN
- 0001-2815 (ISSN-L)
- 1399-0039
- OpenAlex
- W1967113354
- Cited by
- 294
- References
- 83
- FWCI
- 12.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy. https://app.cochat.ai/papers/10.1034/j.1399-0039.2003.00037.x
- The paper
- Van Sorge, N. M., Van Der Pol, W., & Van De Winkel, J. G. J. (2003). FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens. https://doi.org/10.1034/j.1399-0039.2003.00037.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.